Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.5952W HIGH $12.23
Volume
62.57 K
Value Traded
2.01 M
Short % Float
4.89%
Days to Cover
1.8
+4.05%Week
-9.08%1 Month
+73.26%3 Month
+182.42%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
188.47 M
EPS (TTM)
-0.78
P/E Ratio
-
Ent. Value
187.12 M
Total Shares
24.23 M
Float Shares
14.40 M
Insiders
40.57%
Institutions
36.54%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
XGN Catalyst Timeline
Dated clinical, regulatory and corporate events for Exagen Inc.
Past FDA Catalysts and PDUFA Decisions
How XGN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Exagen Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every XGN program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Chernett Jorey10% Owner | Buy | 14,000 2,618,540 held | $7.46 | 10/19/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in XGN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 0 % | 906.75 K | 195.00 K | -50.66% ( -200.23 K) |
XGN Institutional Ownership Trends
XGN Short Interest
Shares sold short, counted twice a month.
4.89%
Short % of Float
of tradable shares sold short
673.9K
Shares Sold Short
-4.4% vs prior count
1.8 Low
Days to Cover
trading days of normal volume to buy every short share back
370.0K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How XGN ranks across every disease it competes in
Competitive Position is a premium feature
See how XGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialXGN News
-XGN
Oct 27, 2026▲ +3.9%today
Exagen to Announce Third Quarter Financial Results on November 10, 2026
Exagen Inc. will release its financial results for Q3 2026 on November 10, 2026. The announcement will be made before market opening, followed by a webcast at 8:00 a.m. ET. The company specializes in autoimmune testing and aims to enhance diagnostic clarity for complex conditions.
Read more →-XGN
Aug 4, 2026▲ +37.8%on this news
Exagen Inc. Reports Second Quarter 2026 Financial Results
Exagen Inc. reported strong financial results for Q2 2026, achieving record revenues and a significant reduction in net loss. The company increased its full-year revenue guidance and highlighted improvements in its testing volume and average selling price. Additionally, a systematic review validated the effectiveness of its AVISE CTD test in diagnosing lupus. Exagen continues to focus on enhancing its leadership in autoimmune diagnostics.
Read more →-XGN
Jul 28, 2026Exagen Inc. to Participate in Upcoming Investor Conference
Exagen Inc. will participate in the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026. The management will engage in a Fireside Chat at 8:30 am ET, which will be available via webcast. Exagen focuses on autoimmune diagnostics and aims to improve patient care through its advanced testing solutions.
Read more →-XGN
Jul 21, 2026Exagen to Announce Second Quarter Financial Results on August 4, 2026
Exagen Inc. will announce its financial results for Q2 2026 on August 4, 2026. The announcement will be made before the market opens, followed by a conference call at 8:30 a.m. ET. The call will be hosted by CEO John Aballi and CFO Jeff Black, providing insights into the company's performance.
Read more →-XGN
Jun 1, 2026▲ +7.4%on this news
Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus
Exagen Inc. announced the publication of a systematic review confirming that its AVISE Lupus algorithm significantly outperforms conventional serologic tests in diagnosing Systemic Lupus Erythematosus (SLE). The study, involving over 1,200 patients, demonstrated enhanced sensitivity and specificity, identifying 25% of patients missed by traditional methods. This reinforces Exagen's competitive position in autoimmune diagnostics.
Read more →-XGN
May 11, 2026▲ +34.9%on this news
Exagen Inc. Reports First Quarter 2026 Results
Exagen Inc. reported strong financial results for Q1 2026, with record revenues of $17.3 million, a 12% increase from the previous year. The company also saw a 10% rise in AVISE CTD test volume and improved its adjusted EBITDA loss. Exagen maintains a positive outlook for the full year, expecting revenues between $70 million and $73 million.
Read more →-XGN
Apr 27, 2026Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026
Exagen Inc. will announce its financial results for Q1 2026 on May 11, 2026, before market opening. CEO John Aballi and CFO Jeff Black will host a conference call at 8:30 a.m. ET to discuss the results. The company specializes in autoimmune diagnostics and aims to enhance patient care through innovative testing solutions.
Read more →-XGN
Mar 3, 2026Exagen Inc. to Participate in Upcoming Investor Conferences
Exagen Inc. announced its participation in two upcoming investor conferences, including the KeyBank Capital Markets Healthcare Forum and the Roth Capital Conference. The events will provide opportunities for investor meetings and discussions about the company's innovative autoimmune testing solutions. Exagen aims to enhance awareness of its diagnostic capabilities for autoimmune conditions.
Read more →-XGN
Feb 24, 2026Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026
Exagen Inc. will announce its financial results for Q4 and the full year of 2025 on March 10, 2026. The announcement will be made before the market opens, followed by a conference call at 8:30 a.m. ET. The company specializes in autoimmune diagnostics and aims to improve patient care through innovative testing solutions.
Read more →-XGN
May 9, 2025▼ -7.3%on this news
Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter s Option to Purchase Additional Shares
Exagen Inc. has successfully closed a public offering, raising approximately $20.2 million by selling 502,500 additional shares at $5.25 each. This offering follows an earlier announcement of a sale of 3,350,000 shares, contributing to the company's financial growth. Canaccord Genuity served as the sole bookrunner for this transaction. The public offering was conducted under a shelf registration statement previously approved by the Securities and Exchange Commission.
Read more →-XGN
May 7, 2025▲ +6.4%on this newsshared move
Exagen Inc. Announces Proposed Public Offering of Common Stock
Exagen Inc. announced a proposed underwritten public offering of its common stock aimed at strengthening its financial position. The offering includes an option for the underwriter to purchase an additional 15% of shares. It will be made under a previously filed shelf registration statement with the SEC. However, the company warns that the offering is subject to market conditions and lacks assurances regarding its completion or actual terms.
Read more →-XGN
Apr 28, 2025▲ +7.1%on this news
Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors
Exagen Inc. has finalized a senior secured credit facility agreement with Perceptive Advisors, securing an initial $25 million to refinance existing debt and enhance its financial stability. The total credit facility amounts to $75 million, with additional funding options available. This strategic partnership is aimed at supporting Exagen's growth initiatives in the autoimmune diagnostics market. However, the company's future performance is contingent on achieving certain milestones and overcoming industry challenges.
Read more →-XGN
Oct 25, 2021Exagen Inc. Announces $27.2 Million Debt Refinancing
Exagen Inc. Announces $27.2 Million Debt Refinancing SAN DIEGO, CA - Exagen Inc. (Nasdaq XGN), a leading provider of autoimmune testing solutions, announced today that it entered into an amendment to its loan and security agreement with its primary lender, an affiliate of Innova
Read more →About Exagen Inc.
Headquarters1261 LIBERTY WAY, VISTA, CA, 92081
BIOPHARMAWATCH ELITE PLUS
Trade the next XGN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime